In silico designing of novel epitope-based peptide vaccines against HIV-1
Biotechnology Letters · 2024-06 · 46 (3) · 315-354
DOI: 10.1007/s10529-023-03464-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Letters, online erschienen am 26.02.2024. Verfasst von Fatemeh Heidarnejad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran. Hauptthemen laut MEDLINE: AIDS Vaccines, HIV Infections, Interferon-gamma, nef Gene Products, Human Immunodeficiency Virus. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 93 Literaturangaben.
Abstract (Originalsprache)
The HIV-1 virus has been regarded as a catastrophe for human well-being. The global incidence of HIV-1-infected individuals is increasing. Hence, development of effective immunostimulatory molecules has recently attracted an increasing attention in the field of vaccine design against HIV-1 infection. In this study, we explored the impacts of CD40L and IFN-γ as immunostimulatory adjuvants for our candidate HIV-1 Nef vaccine in human and mouse using immunoinformatics analyses. Overall, 18 IFN-γ-based vaccine constructs (9 constructs in human and 9 constructs in mouse), and 18 CD40L-based vaccine constructs (9 constructs in human and 9 constructs in mouse) were designed. To find immunogenic epitopes, important characteristics of each component (e.g., MHC-I and MHC-II binding, and peptide-MHC-I/MHC-II molecular docking) were determined. Then, the selected epitopes were applied to create multiepitope constructs. Finally, the physicochemical properties, linear and discontinuous B cell epitopes, and molecular interaction between the 3D structure of each construct and CD40, IFN-γ receptor or toll-like receptors (TLRs) were predicted. Our data showed that the full-length CD40L and IFN-γ linked to the N-terminal region of Nef were capable of inducing more effective immune response than multiepitope vaccine constructs. Moreover, molecular docking of the non-allergenic full-length- and epitope-based CD40L and IFN-γ constructs to their cognate receptors, CD40 and IFN-γ receptors, and TLRs 4 and 5 in mouse were more potent than in human. Generally, these findings suggest that the full forms of these adjuvants could be more efficient for improvement of HIV-1 Nef vaccine candidate compared to the designed multiepitope-based constructs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
- Iranian Comprehensive Hemophilia Care Center, Tehran, Iran.
- Iranian Tissue Bank Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran. azam.bolhassani@yahoo.com.
Zitieren
APA
Heidarnejad, F., Namvar, A., Sadat, S. M., Pordanjani, P. M., Rezaei, F., Namdari, H., Arjmand, S., & Bolhassani, A. (2024). In silico designing of novel epitope-based peptide vaccines against HIV-1. Biotechnology Letters, 46(3), 315-354. https://doi.org/10.1007/s10529-023-03464-x
Vancouver
Heidarnejad F, Namvar A, Sadat SM, Pordanjani PM, Rezaei F, Namdari H, et al. In silico designing of novel epitope-based peptide vaccines against HIV-1. Biotechnology Letters. 2024;46(3):315-354. doi:10.1007/s10529-023-03464-x
BibTeX
@article{Heidarnejad2024,
author = {Heidarnejad, Fatemeh and Namvar, Ali and Sadat, Seyed Mehdi and Pordanjani, Parisa Moradi and Rezaei, Fatemeh and Namdari, Haideh and Arjmand, Sina and Bolhassani, Azam},
title = {In silico designing of novel epitope-based peptide vaccines against HIV-1},
journal = {Biotechnology Letters},
year = {2024},
volume = {46},
number = {3},
pages = {315--354},
doi = {10.1007/s10529-023-03464-x}
}
EUVIMED